BioMedNewsBreaks

WednesdayOct 12, 2022 12:18 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Publication of Innovative Mathematical Model

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to SARS-CoV-2 in a peer-reviewed research paper in the Journal of Theoretical Biology. The publication, titled “A mathematical model of the within-host kinetics of SARS-CoV-2 neutralizing antibodies following COVID-19 vaccination,” describes a model developed with Dr. Lisette de Pillis, a professor of life sciences and mathematics at Harvey Mudd College. NAb inhibit viral binding to the human cell receptor thereby reducing…

Continue Reading

TuesdayOct 11, 2022 1:20 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints Seasoned Veteran as New Chief Medical Officer

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has named a new chief medical officer. Renowned Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will be joining the HeartBeam executive team and will support the planned advancement of the company’s product pipeline. Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School, Fitzgerald is an interventional cardiologist and has led or participated in more than 175 clinical trials and has published some 650 manuscripts/chapters. He has…

Continue Reading

TuesdayOct 11, 2022 12:53 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Formation of Subsidiary Focused on Treating Neurological Disorders

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the formation of Odyssey Neuropharma Inc. According to the update, the wholly owned subsidiary will focus on developing drugs to treat neurological disorders. The blood-brain barrier (“BBB”) represents a significant obstacle for drug delivery to the brain, and many drugs have failed in neuroscience research due to the inability to jump the hurdle that is the BBB. Odyssey will utilize its unique intranasal delivery device coupled with its powdered formulations to allow drugs to be delivered more directly to the brain, providing for quick and…

Continue Reading

TuesdayOct 11, 2022 11:25 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), The Chopra Foundation Note World Mental Health Day

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), joined partner The Chopra Foundation in recognizing World Mental Health Day, which was Monday, Oct. 11, 2022. The two organizations are working together to research the potential of psychedelic-based therapies for the treatment of mental health and to provide education about the use of psychedelics. Founded by Dr. Deepak Chopra, The Chopra Foundation is a not-for-profit organization dedicated to improving health and well-being. World Mental Health Day was designed to create an opportunity for those with mental health issues, along with advocates, governments, employers, employees and…

Continue Reading

MondayOct 10, 2022 1:36 pm

BioMedNewsBreaks – Why HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam (NASDAQ: BEAT) is a cardiac technology company whose initial focus is on providing diagnostic data through its 3D-vector 12-lead electrocardiogram (“ECG”) platform – the first and only to be developed – for heart attack detection anytime, anywhere. Its development portfolio includes HeartBeam AIMI(TM), a software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately and speedily identify a heart attack in acute care settings. Also under development is HeartBeam AIMIGo(TM), the first and only credit card-sized 12-lead output ECG device for remote heart attack detection that combines a smartphone app and cloud-based diagnostic software…

Continue Reading

MondayOct 10, 2022 11:58 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Participate in Breakthrough for Brain Tumors(R) 5K Run

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its Chief Executive Officer John Climaco will participate in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run. The event is taking place on Saturday, Nov. 5, 2022, in Los Angeles, California. “The unmet need in brain tumor treatment is immense and knows no geographic borders. As CEO of CNS, I have come to know many brain tumor patients personally and the optimism and strength with which they have…

Continue Reading

MondayOct 10, 2022 10:27 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Initiates Safety Evaluation Study of Its Novel Time-Released Ketamine Formulation

Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company today announced that it has initiated a preclinical toxicity study of its novel time-released, dosage controlled formulation of ketamine, designated as SP-26, for the treatment of fibromyalgia. “We are working closely with our joint venture partner Zylö Therapeutics in developing a topical sustained released ketamine utilizing Z-pod(TM) technology,” said Eric Weisblum, CEO of Silo Pharma. “Preclinical studies have already shown that our joint developed delivery method and formulation can hold and distribute ketamine in a time-released manner. SP-26 reported positive…

Continue Reading

FridayOct 07, 2022 11:51 am

BioMedNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Featured in FedEx Video Presentation

Aditxt (NASDAQ: ADTX), a biotech innovation company, has announced that its AditxtScore(TM) is featured by FedEx in a video presentation that showcases the various ways in which both companies are playing critical roles in a challenging environment that includes the nation’s response to COVID-19. In the clip, the Aditxt team provides a virtual tour of its AditxtScore(TM) Center and describes the company’s collaboration with scientists and technicians to process samples from around the country to help physicians and health care professionals identify and understand their patients’ immune status. “Aditxt is a biotech innovation company with a very special mission —…

Continue Reading

FridayOct 07, 2022 11:12 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Advancement of Berubicin Clinical Trial Featured in Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio release covers CNS Pharmaceuticals’ recent announcement that highlights the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of glioblastoma multiforme (“GBM”), one of the…

Continue Reading

ThursdayOct 06, 2022 1:11 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate at Upcoming Dawson James Small Cap Growth Conference

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is scheduled to participate in the 7th annual Dawson James Small Cap Growth Conference. Silo Pharma CEO Eric Weisblum will present at the event, which is scheduled for Oct. 12, 2022, in Jupiter, Florida. Weisblum’s presentation will include an overview of Silo Pharma’s acquisition and development of intellectual property and technology rights from leading universities and researchers, including the use of the psychedelic drugs. The presentation will also feature a summary of Silo’s the diversified pipeline, which is focused on underserved rare disease,…

Continue Reading